Shopping Cart
- Remove All
- Your shopping cart is currently empty
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) exhibiting antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,270 | 10-14 weeks | |
50 mg | $2,980 | 10-14 weeks | |
100 mg | $4,000 | 10-14 weeks |
Description | c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) exhibiting antitumor activity. |
Targets&IC50 | c-Met:0.6 nM |
In vitro | c-Met-IN-2 (Compound 14) exhibits weak activity on other kinases, with IC50 values of 731 nM [RON], 1075 nM [AxI], 18364 nM [VEGFR2], 2357 nM [PDGFRa], 5396 nM [c-Kit], and 17056 nM [c-Src]. |
In vivo | In mice bearing H1993 tumors, c-Met-IN-2 (0.1, 1, 10 mg/kg, p.o., once daily) significantly reduces the volume of tumors. c-Met-IN-2 has a similar effect in SNU-5 xenograft model via oral administration at 0.3, 1 and 3 mg/kg. |
Molecular Weight | 484.49 |
Formula | C24H21FN10O |
Cas No. | 1635406-73-3 |
Relative Density. | 1.55 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.